BioMS Medical to present at Sachs Associates Biotech in Europe Forum
EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland.
About Sachs Associates Biotech in Europe Investor Forum
The forum is recognized as the leading international stage for those interested in investing in the biotech and life science industry and is highly transactional, drawing together an exciting cross-section of early-stage/pre-IPO, late-stage and listed companies with leading investors, analysts, money managers and pharmas.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
WHEN: Tuesday September 23rd at 11:25am (Local Time) WHERE: Zurich, Switzerland
SOURCE BioMS Medical Corp.
You May Also Like